Medicamen Biotech Limited (BOM:531146)
India
· Delayed Price · Currency is INR 285.50
-6.00 (-2.06%)
At close: Mar 9, 2026
Medicamen Biotech Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Net Income | - | 71.08 | 109.31 | 148.44 | 148.98 | 121.29 | Upgrade
|
| Depreciation & Amortization | - | 69.1 | 69.19 | 62.56 | 56.72 | 24.55 | Upgrade
|
| Other Amortization | - | 1.56 | 1.74 | 1.1 | 0.99 | 0.65 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | 0 | -0.07 | -0.01 | -0.03 | Upgrade
|
| Other Operating Activities | - | 39.15 | 27.53 | 12.8 | 12.62 | 7.15 | Upgrade
|
| Change in Accounts Receivable | - | -136.4 | 99.99 | -20.35 | -106.76 | -25.89 | Upgrade
|
| Change in Inventory | - | -27.62 | -143.18 | -180.48 | -218.06 | 117.54 | Upgrade
|
| Change in Accounts Payable | - | 37.03 | -86.37 | 42.86 | 110.89 | -51.7 | Upgrade
|
| Change in Other Net Operating Assets | - | -135.48 | -145.65 | -129.8 | 35.73 | -65.85 | Upgrade
|
| Operating Cash Flow | - | -81.59 | -67.44 | -62.93 | 41.09 | 127.72 | Upgrade
|
| Operating Cash Flow Growth | - | - | - | - | -67.83% | -0.24% | Upgrade
|
| Capital Expenditures | - | -21.89 | -62.87 | -66.01 | -86.08 | -179.66 | Upgrade
|
| Other Investing Activities | - | 7.92 | 7.24 | 7.21 | 1.35 | 1.53 | Upgrade
|
| Investing Cash Flow | - | -13.97 | -55.63 | -58.8 | -84.73 | -178.13 | Upgrade
|
| Short-Term Debt Issued | - | - | 62.49 | 40.38 | 83.46 | 33.13 | Upgrade
|
| Long-Term Debt Issued | - | 24.79 | 3.86 | - | - | 40.46 | Upgrade
|
| Total Debt Issued | - | 24.79 | 66.35 | 40.38 | 83.46 | 73.59 | Upgrade
|
| Short-Term Debt Repaid | - | -0.43 | - | - | - | - | Upgrade
|
| Long-Term Debt Repaid | - | - | - | -42.04 | -13.31 | - | Upgrade
|
| Total Debt Repaid | - | -0.43 | - | -42.04 | -13.31 | - | Upgrade
|
| Net Debt Issued (Repaid) | - | 24.36 | 66.35 | -1.66 | 70.15 | 73.59 | Upgrade
|
| Issuance of Common Stock | - | 5.21 | 53.41 | 334.12 | - | 1.55 | Upgrade
|
| Common Dividends Paid | - | -12.72 | -12.65 | -12.65 | -12.22 | -6.11 | Upgrade
|
| Other Financing Activities | - | -31.56 | -43.97 | -28.53 | -14.96 | -10.64 | Upgrade
|
| Financing Cash Flow | - | -14.71 | 63.14 | 291.27 | 42.98 | 58.39 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | - | - | -0 | - | - | Upgrade
|
| Net Cash Flow | - | -110.26 | -59.93 | 169.54 | -0.66 | 7.98 | Upgrade
|
| Free Cash Flow | - | -103.47 | -130.31 | -128.94 | -44.99 | -51.94 | Upgrade
|
| Free Cash Flow Margin | - | -6.18% | -7.27% | -9.15% | -3.90% | -4.61% | Upgrade
|
| Free Cash Flow Per Share | - | -8.14 | -10.29 | -10.19 | -3.68 | -4.25 | Upgrade
|
| Cash Interest Paid | - | 31.56 | 43.97 | 29.23 | 14.01 | 10.64 | Upgrade
|
| Cash Income Tax Paid | - | 13.5 | 30.65 | 26.2 | 32 | 44.6 | Upgrade
|
| Levered Free Cash Flow | - | -122.84 | 23.34 | -86.46 | -84.89 | -32.11 | Upgrade
|
| Unlevered Free Cash Flow | - | -103.12 | 50.83 | -68.2 | -76.13 | -25.46 | Upgrade
|
| Change in Working Capital | - | -262.48 | -275.21 | -287.76 | -178.21 | -25.9 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.